Market Place
Sourcing Support
8-Year Survival with Cure for Liver Cancer with Namodenoson
04 Dec 2024 //
GLOBENEWSWIRE
Patient Improvement Reported With Namodenoson In Liver Cirrhosis
01 Jul 2024 //
GLOBENEWSWIRE
Can-Fite demonstrates Namodenoson`s anticancer and liver protective effects.
24 Jun 2024 //
BUSINESSWIRE
Can-Fite Gets IRB Approval For Pancreatic Cancer Study With Namodenoson
10 Jun 2024 //
BUSINESSWIRE
Can-Fite: Namodenoson Long-Term CR in Advanced Liver Cancer Patient
25 Apr 2024 //
BUSINESSWIRE
Can-Fite: Namodenoson Promising For Liver Cancer, MASH
15 Apr 2024 //
BUSINESSWIRE
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed
11 Mar 2024 //
BUSINESSWIRE
Can-Fite:Complete Response in Patient with Liver Cancer Treated with Namodenoson
21 Nov 2023 //
BUSINESSWIRE
Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives from (ASCO)
30 May 2023 //
BUSINESSWIRE
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Companies
16 Mar 2023 //
BUSINESSWIRE
Novel Approach to Treating Liver Cancer with Namodenoson Published in Journal
14 Feb 2023 //
BUSINESSWIRE
Can-Fite to Present its PhIIb NASH Drug Candidate Namodenoson at Conference
13 Oct 2022 //
BUSINESSWIRE
Can-Fite’s Drug Namodenoson Approved for Treatment of Liver Cancer Patients
23 Aug 2022 //
BUSINESSWIRE
Namodenoson’s Liver Fibrosis Treatment Receives Notice of Allowance from USPTO
14 Mar 2022 //
BUSINESSWIRE
Can Fite Begins Enrollment in Phase IIb NASH Clinical Trial with Namodenoson
31 Jan 2022 //
BUSINESSWIRE
Liver Cancer Patient Treated with Namodenoson Clears All Cancer Lesions
20 Dec 2021 //
BUSINESSWIRE
Can-Fite CEO to Present Namodenoson’s Clinical Trial Data
26 Oct 2021 //
BUSINESSWIRE
Can-Fite’s Namodenoson Abstract Selected as ‘Best of The Liver Meeting
24 Nov 2020 //
BUSINESSWIRE
Can-Fite Receives Notice of Allowance for Namodenoson Patent NASH & NAFLD
21 May 2020 //
BUSINESSWIRE
Can-Fite is Filing Drug Safety Update-Ph II & Ph III Namodenoson & Piclidenoson
03 Mar 2020 //
BUSINESSWIRE
Can Fite Files Patent for Namodenoson to Overcome Drug Resistance
24 Feb 2020 //
BUSINESSWIRE
Can-Fite Granted Patent Allowance for its NASH Drug Namodenoson in South Korea
18 Feb 2020 //
BUSINESSWIRE
Data from the Phase II Liver Cancer Study with Namodenoson will be presented
08 Jan 2020 //
BUSINESS WIRE
Data from the Phase II Liver Cancer Study with Namodenoson will be presented
07 Jan 2020 //
BUSINESS WIRE
Data from the Phase II Liver Cancer Study with Namodenoson will be presented
07 Jan 2020 //
BUSINESS WIRE
USFDA Agreed with Can-Fite’s Proposed Pivotal PhIII Trial to Support a NDA Sub
31 Oct 2019 //
BUSINESSWIRE
Can-Fite Completes Patient Enrollment in Phase II NASH Study of Namodenoson™
15 Oct 2019 //
BUSINESSNEWSWIRE
Drugs with MOA Utilized by Namodenoson Recommended to Combat Liver Cancer
02 Jul 2018 //
BUSINESSWIRE
Can-Fite Reports on New Pre-Clinical Developments with Its NASH Drug Namodenoson
11 Jun 2018 //
BUSINESSWIRE
